Abstract: The present invention relates to isolated DNA encoding novel estrogen receptors, the proteins encoded by said DNA, chimeric receptors comprising parts of said novel receptors and uses thereof.

Abstract: This invention relates to a process for the preparation of anionic clay and boehmite-containing compositions. These compositions may also contain unreacted trivalent metal source and/or divalent metal source. The process involves subjecting a precursor mixture comprising a divalent metal source and a trivalent metal source to at least two aging steps, wherein at least once between two aging steps an aluminum source is added. An advantage of the invention is that the crystallinity of the boehmite in the composition can be tuned.

Abstract: The disclosed invention relates to the unexpected finding of novel steroids which are characterized by a 14&bgr;,15&bgr;-cyclopropane ring and a 17&agr; hydroxymethyl group. These steroids according to the invention are found to have in common an androgenic activity. They can be used for the preparation of an agent for male contraception, as well as for the preparation of a medicament for the treatment of androgen insufficiency.

Abstract: A method for preparing a wet strength agent comprising a first step of reacting a nitrogen-containing polymer with a hydrophobic compound to form hydrophobic side-chain substituents on the polymer, a second step of reacting the hydrophobised nitrogen-containing polymer obtained with a crosslinker to form a cationic nitrogen-containing resin, and a third step comprising forming of particles by emulsion polymerisation of one or more ethylenically unsaturated monomers in the presence of the wet strength resin formed. The invention further relates to a wet strength agent and resin. It further relates to the use of said agent and resin in cellulosic suspensions, the production of paper, preferably tissue paper, and paper, preferably tissue paper comprising a wet strength resin or agent.

Abstract: The present invention provides a NDV mutant which is suited as vaccine candidate for in ovo vaccination. The mutant expresses reduced levels of V protein and can safely be administered to chicken embryos before hatch.

Abstract: The present invention refers to an essentially water-free sizing composition and an aqueous sizing dispersion comprising a sizing agent, a non-ionic surfactant, an anionic surfactant and a monohydric alcohol. The invention also relates to a method for producing an aqueous dispersion comprising the above components and the use of the dispersion for surface and stock sizing.

Abstract: The present invention pertains to cheaper process for the preparation of quasi-crystalline boehmite containing additive in a homogeneously dispersed state. In this cheaper process an inexpensive quasi-crystalline boehmite precursor is and additive are combined and aged to form a quasi-crystalline boehmite containing additive in a homogeneously dispersed state. Suitable inexpensive quasi-crystalline boehmite precursors are aluminum trihydrate and thermally treated forms thereof and inorganic aluminum salts. Suitable additives are compounds containing elements selected from the group of rare earth metals alkaline earth metals, transition metals, actinides, silicon, gallium, boron, and phosphorus.

Abstract: The invention pertains to a coating composition comprising a polyacetoacetate and a crosslinker for said polyacetoacetate wherein the crosslinker is present in an amount insufficient to crosslink all acetoacetate groups and the polyacetoacetate has a number average molecular weight less than 1000. The coating composition may also comprise an organosilane. The organosilane preferably comprises at least one amino group, amino-containing group, epoxy group, epoxy-containing group, mercapto group, mercapto-containing group, vinyl group, vinyl-containing group, isocyanate group, isocyanate-containing group, ureido group, ureido-containing group, imidazole group or imidazole-containing group. The coating composition is particularly useful as a primer for an aluminium substrate.

Abstract: The invention provides non-steroidal estrogenic compounds with estrogenic and anti-estrogenic compounds effects for treatment of estrogen-deficiency related disorders, which compounds are having formula (I) wherein, one of Ra or Rb is 'Re; Re and 'Re are OH, optionally independently etherified or esterified; X is N or —C(R1)—, wherein R1 is H1 halogen, CN, optionally substituted aryl, (1C-4C)alkyl, (2C-4C)alkenyl, (2C-4C)alkynyl or (3C-6C)cycloalkyl, which alkyl, alkenyl, alkynyl and cycloalkyl groups can optionally be substituted with one or more halogens; Y is N or —C(R2)—, with the proviso that X and Y are not both N, wherein R2 has the same meaning as defined for R1; Z is C(R3,'R3)— or —C(R4,∝R4)—C(R5,'R5)—, wherein R3, 'R3, R4, 'R4, R5, and 'R5, independently arc H, (1C-4C)alkyl, (2C-4C)alkenyl or (3C-6C) cycloalkyl, which alkyl, alkenyl and cycloalkyl groups can optionally be substituted with one or more halogens.

Abstract: Pervaporation device for the desalination of salt water comprising a channel or cavity for holding or transporting salt water and a liquid-water-impermeable, water-vapour-permeable non-porous membrane, which is made of a copolyether amide wherein the polyether and (poly)amide segments are linked via amide bridges.

Abstract: The present invention relates to isolated DNA encoding novel estrogen receptors, the proteins encoded by said DNA, chimeric receptors comprising parts of said novel receptors and uses thereof.

Abstract: Disclosed are novel, selective estrogens type having a steroid skeleton with a non-aromatic A-ring and a free or capped hydroxyl group at carbon atom No. 3. The estrogens satisfy general formula (I), in which R1 is H, (C1-C3)alkyl or (C2-C3)acyl; R2 is H, &agr;-(C1-C4)alkyl, &agr;-(C2-C4)alkenyl or &agr;-(C2-C4)alkynyl; R3 is H or (C1-C4)alkyl, (C2-C4)alkenyl or (C2-C4)alkynyl, each at location 15 or 16 of the steroid skeleton; R4 is H or (C1-C5)alkyl, (C2-C5)alkenyl or (C2-C5)alkynyl, each optionally substituted with halogen; preferred is ethynyl; R5 is H, (C1-C3)alkyl or (C2-C3)acyl; R6 is (C1-C5)alkyl, (C2-C5)alkenyl, (C2-C5)alkynyl or (C1-C5)alkylidene, each optionally substituted.

Abstract: The present invention relates to polysilicate microgels, their preparation and use in paper making and water purification, the polysilicate microgels being obtainable by a process which comprises bringing into contact (i) particles of a salt AB with an aqueous silicate or polysilicate solution, (ii) an ion A with an ion B in the presence of an aqueous silicate or polysilicate solution, whereby the salt AB is precipitating in the aqueous phase, or (iii) an ion A with an ion B in the presence of an aqueous silicate or polysilicate solution, whereby the ions A and B represent ions of a precipitable salt AB having a pKS value of at least 4, measured at 20° C. in water. The invention further relates to aqueous silicate or polysilicate solutions, their preparation and use as precursors for polysilicate microgels.

Abstract: An anionic cellulose ether obtainable by a process comprising reacting an alkali metal cellulose with one or more reagents A selected from the group consisting of haloacetic acids, alkali metal haloacetates, alkali metal vinyl sulfonates, vinyl sulfonic acid, and precursors thereof, and one or more reagents B having the formula R1—(OCH2CH(R2))n-P, wherein R2 represents hydrogen or a methyl group; n is 0-2; P represents a glycidyl ether group, a 1,2-epoxy group or a precursor thereof, if P represents a glycidyl ether group, R1 represents a linear C3-C5 alkyl group, optionally containing an oxygen atom, a phenyl group, or a benzyl group, and if P represents a 1,2-epoxy group, R1 represents a linear C3-C5 alkyl group, optionally containing an oxygen atom. Preferably, reagent A is chloroacetic acid and reagent B is n-butyl glycidyl ether. The invention also relates to the use of said anionic cellulose ether as an associative thickener, rheology modifier or stabilizer.

Abstract: Disclosed is a 6-mercapto-cyclodextrin derivative having general formula (I) wherein m is 0-7 and n is 1-8 and m+n=7 or 8; R is (C1-6)alkylene, optionally substituated with 1-3 OH groups, or (CH2)o-phenylene-(CH2)p—; o and p are independently 0-4; X is COOH, CONHR1, NHCOR2, SO2OH, PO(OH)2, O(CH2—CH2—O)q—H, OH or tetrazol-5-yl; R1 is H or (C1-3)alkyl; R2 is carboxyphenyl; q is 1-3; or pharmaceutically acceptable salts thereof. The 6-mercaptocyclodextrin derivative is highly suitable for use in the reversal of drug-induced neuromuscular block.

Abstract: A process for synthesizing a crystalline aluminosilicate zeolite having an MFI structure comprising crystallizing the zeolite from an alkaline aqueous reaction mixture that comprises SiO2 and Al2O3 or their hydrated derivatives, and an amorphous aluminosilicate nucleating gel with an SiO2/Al2O3 ratio of from about 10 to less than 20. The reaction mixture does not contain an organic template.

Abstract: A water borne binder composition comprising (a) an aqueous dispersion of an acrylic copolymer comprising carboxylic acid and ethylene-urea functionality, having a weight average molecular weight below 200,000 and a Tg<−15° C., as calculated from the monomer composition using the Fox equation; and (b) a water soluble complex of a transition metal, preferably zinc.

Abstract: The present invention relates to the use of GDF-9 in assisted reproduction and to kits comprising GDF-9. A method is provided to stimulate follicle and oocyte development and maturation. The method comprises administering GDF-9 in combination with gonadotropins.

Abstract: The invention relates to a spherical catalyst composition comprising a Group VI metal component and optionally a Group VIII metal component on a carrier, which catalyst has a particle size of 0.5-7 mm, a total pore volume of 0.5-1.3 ml/g, an average pore diameter of 15-30 nm, and a % PV(>100 nm) of 2-30%, there being substantially no difference in density between the core region of the carrier particles and their surface regions. The catalyst is particularly suitable for use in non-fixed bed processes for the hydroprocessing of heavy hydrocarbon feeds. It has high hydrodesulfurization and hydrodemetallization activity in combination with a high abrasion resistance.

Abstract: The present invention relates to a method to prevent a premature LH surge. The method employs the administration of the gonadotropin releasing hormone antagonist ganirelix in an amount between 0.125-1 mg in combination with exogenous FSH. The method can be used in the treatment of women undergoing controlled ovarian superovulation.